Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2017-06-28 Director's Dealing
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-06-28 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated June 14, 2017, reporting the submission of matters to a vote of securityholders at the 2017 Annual General Meeting (AGM) of uniQure N.V. It details the voting results on various agenda items such as adoption of annual accounts, discharge of the Board, appointment of directors, authorization for share issuance and repurchase, reappointment of auditor, and amendments to the Articles of Association. The content is focused on the official results of shareholder votes at the AGM, which matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not the AGM presentation itself, nor is it an annual report or other financial report. Therefore, the correct classification is DVA with high confidence.
2017-06-15 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-08 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-07 English
FORM 3 SUBMISSION
Director's Dealing
2017-06-07 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated June 6, 2017. The key content is the announcement of the appointment of Stephen L. Zelenkofske, D.O., as chief medical officer. This is a management change announcement. The document is short (3479 characters) and primarily serves to notify the market of a change in senior management. There are no financial statements or detailed financial data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a proxy, voting result, or other governance document. Therefore, the most appropriate classification is Board/Management Information (MANG).
2017-06-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.